The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Subscribe To Our Newsletter & Stay Updated
